Technical Analysis for REVB - Revelation Biosciences, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 1.95 | 5.69% | 0.11 |
Earnings due: May 20
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Oversold Stochastic | Weakness | 0.00% | |
| MACD Bearish Signal Line Cross | Bearish | 5.69% | |
| NR7 | Range Contraction | 5.69% | |
| Narrow Range Bar | Range Contraction | 5.69% | |
| Inside Day | Range Contraction | 5.69% | |
| Below Lower BB | Weakness | 5.69% | |
| Lower Bollinger Band Touch | Weakness | 5.69% | |
| Oversold Stochastic | Weakness | 5.69% | |
| Stochastic Reached Oversold | Weakness | 5.98% | |
| Below Lower BB | Weakness | 5.98% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakout | about 17 hours ago |
| Up 1% | about 17 hours ago |
| Rose Above Lower Bollinger Band | about 20 hours ago |
| Rose Above Lower Bollinger Band | 1 day ago |
| Up 2% | 1 day ago |
Get this analysis on your stocks daily!
- Earnings date: 05/20/2024
Revelation Biosciences, Inc. Description
Revelation Biosciences, Inc. is a clinical-stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. Revelation has several product candidates in development. REVTx-99, the lead therapeutic candidate, is an intranasal immunomodulator to prevent or treat infections caused by various respiratory viruses such as SARS-CoV-2, including its variants, influenza A and B, parainfluenza, rhinovirus, and RSV. REVTx-99 is also being developed for other indications such as: allergic rhinitis and chronic nasal congestion. REVTx-200 is an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. REVTx-200 is based on the same technology used in REVTx-99. In addition to Revelation’s therapeutic pipeline, Revelation is also developing REVDx-501, a rapid home use diagnostic that can be used to detect any respiratory viral infection, regardless of virus type or strain, without the need for specialized instrumentation.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Clinical Medicine Disease Immunology Infection Vaccination Respiratory Diseases Allergology Nasal Administration Rhinitis
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 39.0 |
| 52 Week Low | 1.7801 |
| Average Volume | 84,468 |
| 200-Day Moving Average | 12.87 |
| 50-Day Moving Average | 2.39 |
| 20-Day Moving Average | 2.15 |
| 10-Day Moving Average | 2.16 |
| Average True Range | 0.22 |
| RSI (14) | 38.65 |
| ADX | 11.39 |
| +DI | 21.31 |
| -DI | 25.13 |
| Chandelier Exit (Long, 3 ATRs) | 1.84 |
| Chandelier Exit (Short, 3 ATRs) | 2.44 |
| Upper Bollinger Bands | 2.45 |
| Lower Bollinger Band | 1.84 |
| Percent B (%b) | 0.18 |
| BandWidth | 28.46 |
| MACD Line | -0.15 |
| MACD Signal Line | -0.14 |
| MACD Histogram | -0.0021 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 2.19 | ||||
| Resistance 3 (R3) | 2.18 | 2.09 | 2.15 | ||
| Resistance 2 (R2) | 2.09 | 2.03 | 2.10 | 2.14 | |
| Resistance 1 (R1) | 2.02 | 1.99 | 2.06 | 2.03 | 2.12 |
| Pivot Point | 1.93 | 1.93 | 1.95 | 1.94 | 1.93 |
| Support 1 (S1) | 1.86 | 1.87 | 1.90 | 1.87 | 1.78 |
| Support 2 (S2) | 1.77 | 1.83 | 1.78 | 1.76 | |
| Support 3 (S3) | 1.70 | 1.77 | 1.75 | ||
| Support 4 (S4) | 1.71 |
